The Treatment of R/R cHL in the Era of Checkpoint Inhibitors

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: November 28, 2018
Expiration Date: November 28, 2019

Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

The treatment landscape for relapsed/refractory classical Hodgkin lymphoma (R/R cHL) is expanding thanks to the development of immunotherapies like checkpoint inhibitors. In this activity, Dr. Catherine Diefenbach summarizes current salvage treatment options for R/R cHL—including their benefits and risks—and discusses the efficacy and safety of immunotherapy in the management of this difficult-to-treat patient population.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including primary care physicians, hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with Hodgkin lymphoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize current optimal salvage regimens
  • Outline how to identify patients unlikely to benefit from HDC and how to best manage their disease
  • Describe the role of immunotherapy in relapsed/refractory HL
  • Summarize a potential future role for combination therapy including immunotherapeutic agents

Agenda

The Treatment of R/R cHL in the Era of Checkpoint Inhibitors – Catherine Diefenbach, MD

Instructions for Participation and Credit

This activity is eligible for credit through November 28, 2019. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Catherine Diefenbach, MD
Assistant Professor of Medicine
Clinical Director of Lymphoma
Department of Hematology/Oncology
NYU Langone Medical Center
New York, New York

Dr. Catherine Diefenbach received her medical degree from the University of Pennsylvania School of Medicine. She completed her internship and residency at the Johns Hopkins Hospital and her oncology fellowship at Memorial Sloan Kettering Cancer Center, where she spent an additional year focusing on translational immunology. Dr. Diefenbach is an Assistant Professor of Medicine, and the Clinical Director of Lymphoma in the Department of Hematology/Oncology at the NYU Langone Medical Center and a member of its Laura and Isaac Perlmutter Cancer Center. Additionally, she directs the lymphoma clinical research within the Hematology Division at the Perlmutter Cancer Center.

Dr. Diefenbach serves on the ECOG Lymphoma Committee, the Grants Committee of the ASCO Conquer the Cancer Foundation, the ASH Communications Committee, and is on the editorial board of Clinical Cancer Research. She is a translational physician-scientist specializing in the care of patients with Hodgkin and non-Hodgkin lymphoma, whose research is supported by the American Cancer Society, the National Cancer Institute (NCI), and the Doris Duke Foundation, and previously by the Lymphoma Research Foundation. Dr. Diefenbach’s scientific research focuses on the relationship between lymphoma and immunity; on developing novel and immune based treatment strategies for patients with relapsed lymphoma; and on biomarker discovery. 

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-043-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosures

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Catherine Diefenbach has received honoraria as a consultant from Bayer AG, Bristol-Myers Squibb Company, Genentech, Inc., Merck & Co., Inc., and Seattle Genetics, Inc. She has received grant support related to research activities from Bristol-Myers Squibb, Genentech, LAM Therapeutics, Inc., MEI Pharma Inc., Merck & Co., Millennium Pharmaceuticals, Inc., and Seattle Genetics. She owns significant holdings in Gilead.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Merck and Co., Inc., and Seattle Genetics, Inc.

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Managing HL would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support of ManagingHodgkinLymphoma.com in 2018.

©2018 MediCom Worldwide, Inc. All rights reserved